Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Gynecologic 2Gastrointestinal 2Breast 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 23Ovarian Neoplasms 20Triple Negative Breast Neoplasms 12Neoplasms 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Glioblastoma 5Astrocytoma 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Gliosarcoma 4Colonic Neoplasms 4Brain Neoplasms 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 3Lymphoma 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Testicular Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × veliparib × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT00804908 2018-06-06

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

AbbVie

Phase 2 Completed
346 enrolled 15 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT00526617 2017-11-21

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

AbbVie

Phase 1 Completed
41 enrolled
BreastDermatologicGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡